Sara Elfarrash

Dr. Sara Elfarrash


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2019 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
SESara Elfarrash
Sara Elfarrash
NJNanna Møller Jensen
Nanna Møller Jensen
Nelson FerreiraNelson Ferreira
Nelson Ferreira
CBCristine Betzer
Cristine Betzer
JTJervis Vermal Thevathasan
Jervis Vermal Thevathasan
PJPoul Henning Jensen
Poul Henning Jensen
Here we describe the use of an organotypic hippocampal slice model for studying α-synuclein aggregation and inter-neuronal spreading initiated by microinjection of pre-formed α-synuclein fibrils (PFFs). PFF injection at dentate gyrus (DG) templates the formation of endogenous α-synuclein aggregates in axons and cell bodies of this region that spread to CA3 and CA1 regions. Aggregates are insoluble and phosphorylated at serine-129, recapitulating Lewy pathology features found in Parkinson’s disease and other synucleinopathies. The model was found to favor anterograde spreading of the aggregates. Furthermore, it allowed development of slices expressing only serine-129 phosphorylation-deficient human α-synuclein (S129G) using an adeno-associated viral (AAV) vector in α-synuclein knockout slices. The processes of aggregation and spreading of α-synuclein were thereby shown to be independent of phosphorylation at serine-129. We provide methods and highlight crucial steps for PFF microinjection and characterization of aggregate formation and spreading. Slices derived from genetically engineered mice or manipulated using viral vectors allow testing of hypotheses on mechanisms involved in the formation of α-synuclein aggregates and their prion-like spreading.

6 October 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SESara Elfarrash
Sara Elfarrash
NJNanna Møller Jensen
Nanna Møller Jensen
Nelson FerreiraNelson Ferreira
Nelson Ferreira
SSSissel Ida Schmidt
Sissel Ida Schmidt
EGEmil Gregersen
Emil Gregersen
PJPoul Henning Jensen
Poul Henning Jensen
Accumulation of aggregated alpha-synuclein (α-syn) is believed to play a pivotal role in the pathophysiology of Parkinson’s disease (PD) and other synucleinopathies. As a key constituent of Lewy pathology, more than 90% of α-syn in Lewy bodies is phosphorylated at serine-129 (pS129) and hence, it is used extensively as a marker for α-syn pathology. However, the exact role of pS129 remains controversial and the kinase(s) responsible for the phosphorylation have yet to be determined. In this study, we investigated the effect of Polo-like kinase 2 (PLK2) inhibition on formation of pS129 using an ex vivo organotypic brain slice model of synucleinopathy. Our data demonstrated that PLK2 inhibition has no effect on α-syn aggregation, pS129 or inter-neuronal spreading of the aggregated α-syn seen in the organotypic slices. Instead, PLK2 inhibition reduced the soluble pS129 level in the nuclei. The same finding was replicated in an in vivo mouse model of templated α-syn aggregation and in human dopaminergic neurons, suggesting that PLK2 is more likely to be involved in S129-phosphorylation of the soluble physiological fraction of α-syn. We also demonstrated that reduction of nuclear pS129 following PLK2 inhibition for a short time before sample collection improves the signal-to-noise ratio when quantifying pS129 aggregate pathology.

29 November 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
NJNanna Møller Jensen
Nanna Møller Jensen
YFYuhong Fu
Yuhong Fu
CBCristine Betzer
Cristine Betzer
HLHongyun Li
Hongyun Li
SESara Elfarrash
Sara Elfarrash
PJPoul Henning Jensen
Poul Henning Jensen
α-Synuclein proximity ligation assay (PLA) has proved a sensitive technique for detection of non-Lewy body α-synuclein aggregate pathology. Here, we describe the MJF-14 PLA, a new PLA towards aggregated α-synuclein with unprecedented specificity, using the aggregate-selective α-synuclein antibody MJFR-14-6-4-2 (hereafter MJF-14). Signal in the assay correlates with α-synuclein aggregation in cell culture and human neurons, induced by α-synuclein overexpression or pre-formed fibrils. Co-labelling of MJF-14 PLA and pS129-α-synuclein immunofluorescence in post-mortem cases of dementia with Lewy bodies shows that while the MJF-14 PLA reveals extensive non-inclusion pathology, it is not sensitive towards pS129-α-synuclein-positive Lewy bodies. In Parkinson’s disease brain, direct comparison of PLA and immunohistochemistry with the MJF-14 antibody shows widespread α-synuclein pathology preceding the formation of conventional Lewy pathology. In conclusion, we introduce an improved α-synuclein aggregate PLA to uncover abundant non-inclusion pathology, which deserves future validation with brain bank resources and in different synucleinopathies.

6 November 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
MWMartina B. William
Martina B. William
SHSharifa Hamed
Sharifa Hamed
ASAli Shalash
Ali Shalash
EKEman M. Khedr
Eman M. Khedr
MYMohamed H. Yousef
Mohamed H. Yousef
MRMie Rizig
Mie Rizig
The impact of LRRK2 variants on the risk of Parkinson’s disease in Egyptians remains unknown. We examined 1210 Egyptians (611 PD patients and 599 controls) from 16 governorates across Egypt for 12 LRRK2 pathogenic variants. The p.Gly2019Ser was the only variant detected, with a prevalence of 4.1% in sporadic cases, 6.5% in familial cases, and 0.68% in controls. Among p.Gly2019Ser carriers, all were heterozygous bar one homozygous patient, and all shared the common haplotype 1. Demographics and UPDRS scores did not differ between carriers and non-carriers, with most patients being males and developed PD in their fifties. Young and Early-onset PD prevalence was 37.5% in carriers and 33% in non-carriers. Familial cases were 16.6% in carriers and 11.5% in non-carriers. This study affirms that like other Mediterranean populations, Egyptians with PD have a higher prevalence of the p.Gly2019Ser variant compared to the global average. LRRK2 inhibitors could be promising therapeutic options for further exploration in this population.

6 August 2024 in Journal of Inflammation
Verified
Journal Article
Open access
PDF file
AMAhmed Sabry Mohamed
Ahmed Sabry Mohamed
MEMahmoud ElKaffas
Mahmoud ElKaffas
KMKarim Metwally
Karim Metwally
MAMahmoud Abdelfattah
Mahmoud Abdelfattah
EEEslam Ashraf Elsery
Eslam Ashraf Elsery
SESara Elfarrash
Sara Elfarrash
Mice transgenic for human P301S tau protein exhibit many characteristics of the human tauopathies, including the formation of abundant hyperphoshorylated tau filaments, the associated neuroinflammation and disease phenotype. However, the exact underpinning mechanisms are still not fully addressed that hinder our understanding of the tauopathy diseases and the development of possible therapeutic targets.Methods: In the current study, hippocampus from three disease time points (2, 4 and 6 months) of P301S mice were further characterized in comparison to the age and sex matched control wild type mice (WT) that do not express the transgene. Different spectrum of hippocampal dependent cognitive tests, biochemical and pathological analysis were conducted to understand the disease progression and the associated changes in each stage. Results: Cognitive impairment was manifested as early as 2 months age, prior to the identification of tau aggregation and phosphorylation by immunostaining. P301S mice manifested an increased pro-inflammatory related changes at mRNA transcription level (IL-1b and IL17A) with the progression of the disease and when compared to the WT mice of the same age. Among the identified genes in the current study, the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) genes expression that is considered as the master regulator of an endogenous inducible defense system was significantly impaired in P301S mice by 4 and 6 months when compared to healthy WT controls. A data that was also supported by the immunostaining of the serial brain sections including the both brain stem and hippocampus. The current result is suggesting that the downregulation of Nrf2 gene and the impaired Nrf2 dependent anti-inflammatory mechanisms in P301S mice brain is possibly contributing -among other factors- in the neuroinflammation and tauopathy, and that modulation of Nrf2 signaling impairments can be further investigated as a promising potential therapeutic target for tauopathy.

29 November 2024 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
SMSara A. Moustafa
Sara A. Moustafa
SDSalima Douhou
Salima Douhou
HHHany Ibrahim Hassanin
Hany Ibrahim Hassanin
MAMohamed Azzam Abdelrahman Ali
Mohamed Azzam Abdelrahman Ali
NSNesma Gamal El Sheikh
Nesma Gamal El Sheikh
MSMohamed Salama
Mohamed Salama